Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | ECHELON-2: brentuximab vedotin and CHP for CD30-positive T-cell lymphomas

Stephen Ansell • 18 Dec 2018
ASH 2018
Lymphoma Non-Hodgkin Lymphoma T-Cell Lymphoma Brentuximab vedotin
ECHELON-2

In this interview, Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MI, discusses the Phase III ECHELON-2 trial (NCT01777152) comparing the efficacy and safety of brentuximab vedotin in combination with CHP vs. the standard of care (CHOP) in patients with CD30-positive T-cell lymphomas. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Ansell reveals the improved outcomes for the patients receiving the brentuximab vedotin regimen, and importantly an improvement in OS; a practice changing result.

More from Stephen Ansell

MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
1:03
What’s on the horizon for Hodgkin lymphoma?
Stephen Ansell • 11 Dec 2023
0:51
Treating patients with Hodgkin lymphoma who are chemo-resistant
Stephen Ansell • 11 Dec 2023
1:21
Hodgkin lymphoma highlights from ASH 2023: nivo-AVD versus BV-AVD in patients with HL
Stephen Ansell • 11 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals